Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
C
Cody Ashby
High Impact
Assistant Professor
Also affiliated: University of Arkansas Medical Center (2020–2025); Winthrop Rockefeller Foundation (2019–2026); Arkansas Biosciences Institute (2014)
Faculty Researcher
25 h-index
177 pubs
3,683 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Cody Ashby's research focuses on the molecular and genomic underpinnings of multiple myeloma and related B cell malignancies. His work investigates the evolutionary pathways from precursor stages to advanced disease, utilizing multi-omics approaches to understand alterations in the tumor microenvironment. Ashby has published research on the role of specific genetic and epigenetic factors in disease progression, including the impact of chromothripsis and TRIP13 modulation on tumor development.
His laboratory group also explores therapeutic strategies, with recent work examining the efficacy of bispecific CAR-T cells in controlling multiple myeloma growth. Additionally, Ashby's research has identified mechanisms by which certain factors, such as CST6, can suppress disease-related complications like osteolytic bone disease. He has a significant publication record, with an h-index of 25 and over 3,600 citations, and collaborates extensively with researchers at the University of Arkansas for Medical Sciences, including Fenghuang Zhan, John D. Shaughnessy, Carolina Schinke, and Sharmilan Thanendrarajan.
Metrics
- h-index: 25
- Publications: 177
- Citations: 3,683
Selected Publications
-
Rnd3 regulates lung cancer cell invasion and migration independently of ROCK1 signaling via alpha 5 integrin modulation (2026)
-
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Additional file 1 of Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Additional file 1 of Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Applying computational modelling to a high-risk multiple myeloma data set to create novel risk stratification groupings (2025)
-
How Does Age at Diagnosis Influence Multiple Myeloma Survival? Empirical Evidence (2025)
-
Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans (2025)
-
The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes - insights from a single-site study (2025)
-
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging (2025)
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)
-
Abstract 2645: Rnd3 depletion in lung cancer cell lines decreases cell invasion and migration in a ROCK1 independent manner (2025)
-
Identification of Risk Factors for Myeloma Progression in African American Patients (2024)
-
Single Nuclei Multiomic Profiling of Transcriptional and Chromatin Accessibility of Tumor Cells Underlines Extensive Cis-Regulatory Interaction during Multiple Myeloma Progression (2024)
Grants & Funding
As listed on this researcher's institutional profile.
- Contribution of osteocytes to the musculoskeletal effects of Multiple Myeloma NIH
- CD24 Tumor-initiating cell as a novel therapeutic target in myeloma US Department of Defense
- TRI KL2 Scholars award - Ashby UAMS College of Medicine
Collaboration Network
Top Collaborators
Carolina Schinke
University of Arkansas for Medical Sciences
25 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Showing 5 of 25 shared publications
Frits van Rhee
Winthrop Rockefeller Foundation
22 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Showing 5 of 22 shared publications
Sharmilan Thanendrarajan
Winthrop Rockefeller Foundation
19 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Showing 5 of 19 shared publications
Maurizio Zangari
Winthrop Rockefeller Foundation
19 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Showing 5 of 19 shared publications
Michael Bauer
University of Arkansas for Medical Sciences
13 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Chromothripsis as a pathogenic driver of multiple myeloma
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- Structural variants shape the genomic landscape and clinical outcome of multiple myeloma
Showing 5 of 13 shared publications
John D. Shaughnessy
University of Arkansas for Medical Sciences
13 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activity
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
Showing 5 of 13 shared publications
Gareth J. Morgan
NYU Langone Health (US)
12 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Chromothripsis as a pathogenic driver of multiple myeloma
- Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers
- Structural variants shape the genomic landscape and clinical outcome of multiple myeloma
Showing 5 of 12 shared publications
Brian A. Walker
Indiana University Health (US)
12 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Chromothripsis as a pathogenic driver of multiple myeloma
- Epigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers
- Structural variants shape the genomic landscape and clinical outcome of multiple myeloma
Showing 5 of 12 shared publications
Samer Al Hadidi
Winthrop Rockefeller Foundation
12 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
Showing 5 of 12 shared publications
Fumou Sun
Winthrop Rockefeller Foundation
11 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 11 shared publications
David E. Mery
Winthrop Rockefeller Foundation
11 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 11 shared publications
Clyde Bailey
Winthrop Rockefeller Foundation
11 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 11 shared publications
Fenghuang Zhan
University of Arkansas for Medical Sciences
10 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activity
- Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
Showing 5 of 10 shared publications
Faith E. Davies
NYU Langone Health (US)
10 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Chromothripsis as a pathogenic driver of multiple myeloma
- Structural variants shape the genomic landscape and clinical outcome of multiple myeloma
- Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
Showing 5 of 10 shared publications
Hayley M. Sabol
University of Arkansas for Medical Sciences
10 shared publications
In database
- Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma
- Abstract 5672: Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
Showing 5 of 10 shared publications
Similar Researchers
Based on overlapping research topics
Charles P. Mercado
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Cells and Metastasis
Disease Mechanisms Research
Clyde Bailey
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Disease Mechanisms Research
Immune Response and Inflammation
Karthikeyan Mythreye
University of Arkansas for Medical Sciences
Cancer Cells and Metastasis
Disease Mechanisms Research
Cancer-related molecular mechanisms research
Yan Cheng
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Cells and Metastasis
Disease Mechanisms Research
Aric Anloague
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Cells and Metastasis
Disease Mechanisms Research
Thomas J. Kelly
University of Arkansas for Medical Sciences
Cancer Cells and Metastasis
Disease Mechanisms Research
Immune Response and Inflammation